Company Description
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors.
The company’s two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition.
The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab.
Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Stephen Brady |
Contact Details
Address: 2000 Sierra Point Parkway, Suite 400 Brisbane, California 94005 United States | |
| Phone | 415 798 8589 |
| Website | tempesttx.com |
Stock Details
| Ticker Symbol | TPST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001544227 |
| CUSIP Number | 87978U108 |
| ISIN Number | US87978U1088 |
| Employer ID | 45-1472564 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen R. Brady J.D., LLM | Chief Executive Officer, President and Director |
| Nicholas Maestas | Vice President of Strategy and Finance and Secretary |
| Dr. Samuel Whiting M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Lindsay Young | Head of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 29, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 10, 2024 | 8-A12B/A | Filing |
| Oct 10, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 144 | Filing |
| Aug 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 9, 2024 | 144 | Filing |
| Aug 8, 2024 | 10-Q | Quarterly Report |